Thoughts on Careers in Biopharm (and More) from Our Scholarship Winners

Posted by ISPE Boston
On August 27, 2020

Congratulations to 2020 Joel Goldenberg Memorial Scholarship winners Maggie Cai, Mark DeSimone and Emma Sinkus, all of whom are planning careers in our industry and excel in both academics and service to the community. We asked them to share their thoughts about winning the scholarships, their future career plans, our industry and the pandemic: Maggie […]

Momenta to be Acquired by J&J for $6.5 Billion

Posted by ISPE Boston
On August 20, 2020

Momenta Pharmaceuticals has agreed to be acquired by Johnson & Johnson for $52.50 per share in an all-cash transaction, implying a fully-diluted equity value of $6.5 billion. The agreement was unanimously approved by the Boards of Directors of both Momenta and Johnson & Johnson. “The agreement with J&J recognizes the value created by years of […]

Sanofi to Acquire Principia for $3.6 Billion

Posted by ISPE Boston
On August 20, 2020

Sanofi and San Francisco-based Principia Biopharma have entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash, which represents an aggregate equity value of approximately $3.68 billion (on a fully diluted basis). Principia Biopharma is a late-stage biopharma focused on developing treatments […]

Tango and Gilead to Expand Collaboration

Posted by ISPE Boston
On August 20, 2020

Gilead Sciences and Cambridge-based Tango Therapeutics have announced an expanded strategic collaboration focused on the discovery, development and commercialization of innovative targeted immune evasion therapies for patients with cancer. Under the expanded multi-year collaboration, which builds on an agreement signed in 2018, Tango will continue to leverage its proprietary, CRISPR-enabled functional genomics target discovery platform […]

Industry Veterans Provide Career Insights

Posted by ISPE Boston
On August 19, 2020

Interested in advice from respected industry professionals on how to achieve your career goals and navigate unexpected career turns? Then we’re sure you tuned in for the Chapter’s first career development “fireside chat” when Haroon Hashmi of Ziopharm Oncology and Jane Rhodes of Verge Genomics settled in for a virtual Q & A with moderator […]

Vote for the 2020 ISPE International Board of Directors!

Posted by ISPE Boston
On August 13, 2020

Have you voted in the 2020 ISPE International Board of Directors election yet? As an ISPE Member, you can help shape the future of the Society by voting for representatives to fill open seats. The Board establishes the Society’s vision and mission, articulates strategic priorities, and ensures that business operations are consistent with ISPE policies, […]

Moderna Inks Deal with U.S. for 100 Million Doses of Vaccine

Posted by ISPE Boston
On August 13, 2020

The U.S. government has secured 100 million doses of Moderna’s vaccine candidate mRNA-1273 as part of the goal of securing early access to safe and effective COVID-19 vaccines for the American people. The award of up to $1.525 billion is for the manufacturing and delivery of 100 million doses of mRNA-1273 including incentive payments for timely delivery of the product. […]

Biogen’s Alzheimer’s Drug Granted Priority Review by FDA

Posted by ISPE Boston
On August 13, 2020

Biogen and Eisai today announced that the FDA has accepted the Biologics License Application (BLA) for aducanumab, an investigational treatment for Alzheimer’s disease. Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement. Since October 2017 Biogen and Eisai have collaborated on the development and commercialization of aducanumab globally. The application has been […]

Biogen to Pay $1 Billion for Rights to Parkinson’s Drug

Posted by ISPE Boston
On August 13, 2020

Biogen and Denali Therapeutics have signed a binding agreement to co-develop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease. Biogen will also receive rights to opt into two programs and a right of first negotiation for two additional programs, in each case for neurodegenerative diseases leveraging Denali’s Transport […]

Seres Therapeutics Phase 3 Study Shows Positive Results

Posted by ISPE Boston
On August 13, 2020

Cambridge-based Seres Therapeutics has reported positive topline results from its Phase 3 study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI). “Based on our prior discussions with the FDA, we believe this trial should provide the efficacy basis for submitting an application for product approval. We look forward to meeting with the […]

Page 61 of 118«‹59 606162 63 ›»